Evidence map›Paper›PMID 42604415›Full record

ArticleArchives of Iranian medicine2026

Quality of Service and Cost of Managing an Episode of Major Depressive Disorder: A Cohort Study in Iran.

Masoumeh Amin-Esmaeili, Shahab Baheshmat, Afarin Rahimi-Movaghar, Seyed Mehdi Samimi Ardestani, Roya Samadi, Ahmad Hajebi, Yosef Farzy, Ebrahim Moghimi-Sarani, Shahab Khatibzadeh, Saeid Shahraz

Abstract read
In one paragraph

Article in Archives of Iranian medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Masoumeh Amin-EsmaeiliMental Health Department, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID 0000-0002-3888-3254
Shahab BaheshmatDepartment of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine (SATiM), Tehran University of Medical Sciences, Tehran, Iran.
Afarin Rahimi-MovagharIranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-5761-1668
Seyed Mehdi Samimi ArdestaniDepartments of Psychiatry, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Roya SamadiResearch Center for Psychiatry and Behavioral Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Ahmad HajebiResearch Center for Addiction and Risky Behaviors (ReCARB), Psychiatric Department, Iran University of Medical Sciences, Tehran, Iran.
Yosef FarzyNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Ebrahim Moghimi-SaraniResearch Center for Psychiatry and Behavior Science, Shiraz University of Medical Sciences, Shiraz, Iran.
Shahab KhatibzadehHeller School of Social Policy and Management, Brandeis University, Waltham, Massachusetts, USA.
Saeid ShahrazTufts Medical Center, Institute for Clinical Research and Health Policy Studies, Boston, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMajor depressive disorder (MDD), a major cause of the burden of diseases, is associated with a considerable rate of inadequate treatment and high costs. We assessed the pattern of service use, quality, and costs of healthcare for MDD in Iran.

methodsWe assessed a national sample of 265 patients in the acute phase of MDD recruited from outpatient/inpatient settings at baseline and in three follow-up points of one, three, and six months. The pattern of service use and selected quality indicators were assessed, and the costs of care for an episode of MDD were estimated using the bottom-up approach.

resultsThe subjects were primarily female (73.6%), with a mean age of 43.3 years (±13.8). Of 173 respondents at the end of the study, 65.3% were on treatment for at least six months. Regarding quality indicators, the majority of the patients (97.7%) were prescribed antidepressants. However, only 71.2% of the patients initiated their antidepressants following prescription at the initial visit. At the end of the study, 40.1% were in remission and 58.1% had at least a 50% improvement in depressive symptoms. However, no standardized process or outcome measures were documented on the patients' medical records. The average out-of-pocket and total costs for an episode of MDD per patient were estimated at Int$ 1331.4 and 2107.4, respectively.

conclusionWe recommend establishing an infrastructure for monitoring the clinical evaluation and treatment, and proper documentation based on standard quality of care, especially for ambulatory clinical practice.

Indexed as

Antidepressive AgentsHealth Care CostsMajor Depressive DisorderQuality of Health CareAdultCohort StudiesFemaleHumansIranMaleMiddle AgedQuality Indicators, Health CareAntidepressive AgentsAffective disordersDepressionEconomic evaluationHealth service

Identifiers

PMID42604415
PMCPMC13338498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.